How Does Allergy Immunotherapy Work? SCIT, SLIT and OIT Compared
All forms of allergy immunotherapy — SCIT (shots), SLIT (sublingual drops or tablets), and OIT (oral food immunotherapy) — share the same core mechanism: repeated allergen exposure induces IgG4 blocking antibodies, Treg induction, and gradual IgE decline. Delivery route differs: SCIT is subcutaneous, SLIT works through oral mucosa, and OIT through gut-associated lymphoid tissue. SCIT and SLIT show comparable long-term efficacy for aeroallergens.
7 peer-reviewed sources
All allergy immunotherapy works by repeatedly exposing the immune system to allergen proteins in controlled increasing doses, triggering IgG4 blocking antibody production, regulatory T-cell induction, and gradual IgE decline. SCIT, SLIT, and OIT achieve this through different delivery routes.
The Shared Immune Mechanism Behind All Allergy Immunotherapy
Whether delivered by injection, sublingual drop, or oral ingestion, all forms of allergen immunotherapy exploit the same fundamental immunological principle: the immune system can learn to tolerate proteins it previously overreacted to, when those proteins are introduced repeatedly in a carefully controlled, graduated exposure protocol.
The shared mechanism has four steps that unfold over months to years: dendritic cell activation in a tolerogenic context; production of IgG4 blocking antibodies that intercept allergens before they can trigger IgE-mediated mast cell degranulation; induction of FOXP3+ regulatory T-cells (Tregs) and IL-10-secreting Tr1 cells that suppress the Th2 allergy-driving immune response; and gradual decline of allergen-specific IgE as IgG4 reaches 10–100 times its pre-treatment baseline.
Where the three modalities differ is in the anatomical route that allergen takes to reach the immune system — and this route difference has significant practical implications for safety, convenience, and efficacy profile. Understanding this can help you choose the immunotherapy approach that fits your life.
Identifying your specific allergen triggers through testing is the prerequisite for any immunotherapy modality — at-home IgE testing options like Curex cover 40+ allergens and can determine your sensitization profile without a clinic visit, providing the data needed to choose the right immunotherapy delivery route.
All three immunotherapy delivery routes — subcutaneous, sublingual, and oral — activate the same core immune tolerance mechanism, but differ in their safety profile, onset speed, and the type of allergy they best treat.
The Four-Step Immunological Mechanism Shared By All Immunotherapy
The immunological sequence that produces allergy tolerance through immunotherapy is well characterized across all delivery routes. Each step builds on the previous, which is why the treatment requires years and why early stopping reduces durability.
Tolerogenic Dendritic Cell Activation
When allergen proteins contact the immune-sensing cells at the delivery site — dermal dendritic cells for SCIT, oral Langerhans cells for SLIT, gut-associated antigen-presenting cells for OIT — these cells present the allergen to T-cells in a tolerogenic rather than inflammatory context. Repeated low-dose exposure drives this tolerogenic presentation, beginning the shift away from the Th2-polarized allergic response.
IgG4 Blocking Antibody Production
Within weeks to months of starting immunotherapy, the immune system begins producing allergen-specific IgG4 antibodies. These blocking antibodies compete with IgE for allergen binding — intercepting allergen proteins before they can cross-link IgE on mast cells and basophils. Research by Shamji and Durham (JACI 2017) shows IgG4 reaches 10–100 times baseline after years of treatment, providing sustained allergen interception capacity.
Regulatory T-Cell Induction
The hallmark of true immunological tolerance is the induction of FOXP3+ regulatory T-cells (Tregs) and IL-10-secreting Tr1 cells that actively suppress the Th2 immune response driving allergy. This is the step that distinguishes disease modification from symptom masking — the immune system is genuinely relearning how to respond to the allergen. The prevention of new sensitizations and asthma development documented in the PAT study (Jacobsen et al., Allergy 2007) is a downstream consequence of this regulatory shift.
Sustained IgE Decline and Mucosal Tolerance
Over years of treatment, allergen-specific IgE gradually decreases as the regulatory T-cell-dominated immune environment suppresses IgE class-switching. This IgE decline, combined with high IgG4 levels, produces the lasting tolerance that persists 3–12 years after discontinuing treatment. The persistence of benefit after treatment ends is the defining characteristic of disease modification — not achievable with antihistamines or other symptom-suppressing approaches.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSCIT vs. SLIT vs. OIT: Comparing the Three Immunotherapy Routes
The same core mechanism, three different pathways. This comparison covers the practical differences that matter for treatment decisions: route, efficacy, safety profile, appropriate indications, and post-treatment durability.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
Allergy Shots (SCIT)Best | Strongest evidence base (100+ years); 33-85% symptom reduction; disease-modifying | 3-5 years; weekly build-up, monthly maintenance; benefits last 3-12 years after stopping | $4,000-20,000 (insurance usually covers) | Weekly then monthly dosing with a brief 30-min self-observation; traditionally an allergist office, now self-administered at home with Curex for eligible patients, first dose and dose changes supervised over Zoom | 0.1-0.2% systemic reaction rate per injection; anaphylaxis possible; safe at-home self-administration for eligible maintenance patients via USP <797> serum, prescribed epinephrine on hand, Zoom-supervised dosing, and gradual escalation |
Sublingual Drops/Tablets (SLIT) | Comparable to SCIT for aeroallergens; slightly slower initial response; disease-modifying | 3-5 years; daily administration; benefits persist after stopping | $2,340+ at home; tablets $6,000-18,000 at pharmacy prices | Daily drops or tablet at home; no clinic visits; no observation period needed | Anaphylaxis less than 1 per 100 million doses; local oral itching most common; safer than SCIT |
Oral Immunotherapy (OIT) | Effective for food desensitization; peanut OIT (Palforzia) FDA-approved 2020 | Ongoing maintenance dosing typically required; desensitization rather than full tolerance | $10,000-30,000 (Palforzia currently $890/month) | Daily home ingestion after supervised build-up; requires food allergy specialist | Higher reaction rate than SLIT; systemic reactions in up to 5% of doses during build-up |
- Efficacy
- Strongest evidence base (100+ years); 33-85% symptom reduction; disease-modifying
- Duration
- 3-5 years; weekly build-up, monthly maintenance; benefits last 3-12 years after stopping
- Cost (5yr)
- $4,000-20,000 (insurance usually covers)
- Convenience
- Weekly then monthly dosing with a brief 30-min self-observation; traditionally an allergist office, now self-administered at home with Curex for eligible patients, first dose and dose changes supervised over Zoom
- Safety
- 0.1-0.2% systemic reaction rate per injection; anaphylaxis possible; safe at-home self-administration for eligible maintenance patients via USP <797> serum, prescribed epinephrine on hand, Zoom-supervised dosing, and gradual escalation
- Efficacy
- Comparable to SCIT for aeroallergens; slightly slower initial response; disease-modifying
- Duration
- 3-5 years; daily administration; benefits persist after stopping
- Cost (5yr)
- $2,340+ at home; tablets $6,000-18,000 at pharmacy prices
- Convenience
- Daily drops or tablet at home; no clinic visits; no observation period needed
- Safety
- Anaphylaxis less than 1 per 100 million doses; local oral itching most common; safer than SCIT
- Efficacy
- Effective for food desensitization; peanut OIT (Palforzia) FDA-approved 2020
- Duration
- Ongoing maintenance dosing typically required; desensitization rather than full tolerance
- Cost (5yr)
- $10,000-30,000 (Palforzia currently $890/month)
- Convenience
- Daily home ingestion after supervised build-up; requires food allergy specialist
- Safety
- Higher reaction rate than SLIT; systemic reactions in up to 5% of doses during build-up
Curex delivers the subcutaneous route — the same IgG4-blocking, Treg-inducing mechanism described above — at home for $129/month. The serum is personalized and sterile-compounded to USP <797>, prescribed and overseen by a board-certified allergist; your first injection and every dose change are supervised live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand, and dosing escalates gradually week by week, making safe at-home self-administration possible for eligible maintenance patients.
See if at-home shots are right for youFrequently asked questions
Is sublingual immunotherapy as effective as allergy shots?
For aeroallergens — pollen, dust mites, pet dander — clinical evidence shows SLIT and SCIT achieve comparable long-term efficacy for symptom reduction. A systematic comparison by Chelladurai et al. (JACI In Practice 2013) found similar outcomes between the two modalities over matched treatment durations. SCIT may produce a faster initial response in some patients because subcutaneous injection delivers allergen more directly to the systemic immune system than sublingual absorption. However, SLIT's substantially better safety profile — anaphylaxis rates less than 1 per 100 million doses compared to 0.1–0.2% per SCIT injection — means the overall benefit-risk ratio is favorable for SLIT in many patients, particularly those with milder sensitization or those who cannot attend weekly clinic appointments during build-up.
What is the difference between SCIT, SLIT, and OIT?
SCIT (subcutaneous immunotherapy) delivers allergen extract by injection under the skin. It requires weekly clinic visits during build-up and monthly visits during maintenance, administered by trained medical staff. SLIT (sublingual immunotherapy) delivers allergen extract or tablet under the tongue. FDA-approved SLIT tablets exist for grass pollen (Grastek), ragweed (Ragwitek), and dust mite (Odactra); prescription-compounded sublingual drops treat a broader allergen range. SLIT is taken at home daily. OIT (oral immunotherapy) is for food allergies — gradually increasing amounts of the food are consumed orally under medical supervision. Palforzia is FDA-approved for peanut OIT. OIT is not interchangeable with SCIT or SLIT; it treats a completely different category of allergy through a different anatomical pathway. All three share the same core mechanism of graduated allergen exposure to induce immune tolerance.
How long does it take for allergy immunotherapy to show results?
For SCIT (allergy shots), most patients notice meaningful symptom improvement within 3–6 months — during the late build-up or early maintenance phase — when IgG4 blocking antibodies have accumulated to therapeutically significant levels. Full disease modification develops over 12–18 months of consistent treatment. For SLIT, the onset timeline is similar or slightly longer in some patients. A Cochrane review found statistically significant symptom reduction within the first treated pollen season for both modalities. The maximum benefit of both SCIT and SLIT develops after 2–3 years of consistent treatment — the same core immune tolerance mechanism operates on a similar timeline regardless of delivery route. For OIT, food-allergic patients often achieve a degree of protection faster, but the desensitization may require ongoing maintenance dosing to sustain.
Can allergy immunotherapy be done at home?
Yes — both modalities can be done at home. SLIT (sublingual drops and tablets) is taken at home daily after an initial physician evaluation and prescription. SCIT (allergy shots) was traditionally administered in a medical facility because of its 0.1–0.2% systemic reaction rate per injection, but a personalized USP <797> sterile-compounded serum combined with telehealth now makes safe at-home self-administration possible for eligible maintenance patients: Curex confirms a prescribed epinephrine auto-injector is on hand, supervises the first injection and every dose change live over Zoom, escalates the dose gradually week by week, and keeps a board-certified allergist overseeing the plan. The first dose of any immunotherapy is observed for reactions, after which supervised home administration improves adherence for patients who struggle with the weekly clinic schedule.
Do allergy shots and sublingual drops treat the same allergens?
SCIT (allergy shots) can treat a broad range of environmental allergens: grass and tree pollens, weed pollens, dust mites, animal danders, mold spores, and insect venoms — over 100 allergen extracts are available. SLIT has narrower FDA-approved coverage: specific grass pollens (Grastek), short ragweed (Ragwitek), and house dust mites (Odactra) in tablet form. Prescription-compounded sublingual drops cover a broader allergen range comparable to SCIT. OIT treats food allergens through a completely different protocol. For patients with multiple sensitizations to uncommon allergens, SCIT currently offers more comprehensive coverage through custom multi-allergen vials. For the most common aeroallergens (grasses, dust mites, ragweed), both SCIT and SLIT provide effective treatment with comparable long-term outcomes.
What new forms of allergy immunotherapy are in development?
Several novel immunotherapy approaches are in active research and clinical trials. Intralymphatic immunotherapy (ILIT) delivers allergen directly into inguinal lymph nodes via injection, potentially achieving equivalent tolerance with only 3–6 injections compared to the hundreds required for SCIT — research by Senti et al. (PNAS 2008) showed promising early results. Epicutaneous immunotherapy (EPIT) uses allergen-containing skin patches (Viaskin technology) that deliver allergen through intact skin — relevant particularly for peanut allergy in young children. Modified allergen vaccines using allergen peptides (T-cell epitopes without IgE-binding capacity) aim to maintain efficacy while eliminating anaphylaxis risk. Recombinant hypoallergens and fusion proteins that trigger tolerance without triggering IgE are in clinical development. These approaches aim to maintain the disease-modifying benefits of immunotherapy while reducing the duration, frequency, and safety risks of current protocols.
Does allergy immunotherapy work for all allergy types?
Allergy immunotherapy is specifically designed for IgE-mediated allergic conditions — environmental aeroallergens (pollen, dust mites, pet dander, mold), stinging insect venom allergy, and some food allergies (OIT). It does not work for non-IgE-mediated reactions, contact dermatitis, irritant reactions, drug allergies (which use different desensitization protocols), or chronic urticaria not driven by allergen exposure. Within IgE-mediated allergy, efficacy varies by allergen type: venom immunotherapy is the most curative (80–95% success), grass pollen and dust mite immunotherapy have the strongest evidence base among aeroallergens, and mold and cockroach immunotherapy have more limited evidence. The fundamental requirement is a confirmed IgE sensitization to the target allergen — a prerequisite that requires specific allergy testing before any immunotherapy modality can be selected.
Related Articles
How Long Do Allergy Shots Take? Trial vs Reality | Curex
How long do allergy shots take to work? Trials show 12-month benefit, but only 23% complete 3 years. Real-world vs clinical data guide.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.